Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients ...
Breyanzi has shown significant efficacy and durable responses in patients with marginal zone lymphoma. Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 ...
The National Institute for Health and Care Excellence (NICE) has approved the use of zanubrutinib (Brukinsa, BeiGene) on the NHS in England for the treatment of marginal zone lymphoma (MZL).
Hosted on MSN
Antibody shows encouraging results for treating high-risk follicular lymphoma and marginal zone lymphoma
Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers—follicular lymphoma and marginal zone ...
Verismo Therapeutics Inc. has submitted an IND application to the FDA seeking to initiate a phase I trial this year of Synkir-310 for the treatment of relapsed or refractory B-cell non-Hodgkin ...
Innovent Biologics Inc, a biopharmaceutical company, announced data from two ongoing phase 2 studies evaluating parsaclisib, an Incyte-discovered, potent, highly selective, next-generation oral ...
In a flurry of updates Monday, ADC Therapeutics revealed that it's selling $105 million in new shares while also touting results for antibody-drug conjugate Zynlonta from a small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback